The pharma centers of Basel and India are influencing each other
Basel has long been one of the world’s most important locations within the pharmaceutical industry. But pharma firms are now starting to play an even bigger role in India as well. Both locations are influencing each other, as shown by the recently ended BioAsia event.
Anke Hollnagel, Director Asia at BaselArea.swiss
Large Indian pharma companies are currently focusing on generics and biosimilars in particular, while Basel-based firms such as Novartis and Roche carry out large-scale research projects, as detailed in a guest article on swissinfo.ch by Anke Hollnagel, Director Asia of the local business promotion organization BaselArea.swiss. However, there are also parallels and mutually beneficial influences between the two locations.
In this way, four startups based in Basel – namely Cellestia, Bottmedical, Artidis und Noul – presented their businesses within the framework of the BioAsia India event, which was held in Hyderabad on February 17-20, 2020. The Swiss delegation came at the initiative of Switzerland Global Enterprise (S-GE), a Swiss foreign trade promotion organization. The delegation also included representatives from BaselArea.swiss, which promoted the economic area of Basel at the event.
However, the interest is ever stronger in the other direction, as Anke Hollnagel notes in her article. In this context, Basel is becoming an attractive location for ever more Indian firms. These companies are active particularly in the areas of the Internet of Things (IoT), Artificial Intelligence (AI) and Machine Learning, and they are offering their services to Basel-based firms operating in the field of life sciences. In this way, they are driving the development of the life sciences sector towards digital healthcare and data-led personalized medicine. According to Anke Hollnagel, this influence will increase yet further over the coming years as Indian firms develop. The major Indian pharma group Dr. Reddy’s has already established a strong presence in Basel.
BaselArea.swiss recognized this development a long time ago and has placed a stronger focus on the Indian market in the past year. This focus will be sustained throughout 2020 as well.
Share this article
You might also be interested in
Moderna is opening a location in Basel and is advancing the production of the coronavirus vaccine from there. The Swiss government has just signed a supply contract with the US company for 4.5 million doses of the vaccine.Read More
The Japanese conglomerate Yokogawa has established a Swiss subsidiary based at the Switzerland Innovation Park Basel Area. Here, the focus will be on driving forward innovation in the field of biotechnology.Read More
The Werner Siemens Foundation is to invest an additional 12 million Swiss francs in the Miracle project. Researchers at the University of Basel are developing visionary technology for the use of robots in surgery within the framework of this project.Read More
The Basel-based biopharmaceutical company Versameb has successfully closed a seed financing round. Versameb develops therapies on the basis of mRNA sequences and is now seeking to drive forward the clinical development of its platform devised for this.Read More
Two thirds of the value added attributable to the pharmaceutical industry as a whole in Switzerland is generated in the Basel Area, as revealed by an Interpharma report. However, the region also shines in an international comparison. Interpharma CEO René Buholzer regards it as “probably the most productive life sciences location in the world”.Read More
Resistell AG, based in Muttenz in the canton of Basel-Landschaft, has received a grant of up to 2.5 million euros and additional equity capital financing from a European fund with the aim of accelerating innovation. The company is developing the world’s fastest test against antibiotic resistance.Read More